HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study

doi:10.1016/j.ejca.2022.12.019

CNU IR > Offices > 456 > Item 310902800/34931

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34931

Title:	HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study
Authors:	Chen, Po-Chuan Yeh, Yu-Min Chu, Chun-Ting Su, Pei-Fang Chiu, Pin-Hsuan Lin, Bo-Wen Chen, Shang-Hung Lin, Peng-Chan Lee, Chung-Ta Chen, Helen H. W. Chen, Chien-Chin
Contributors:	Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Colorectal Surg Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Surg, Div Colorectal Surg Natl Cheng Kung Univ, Dept Stat Natl Cheng Kung Univ Hosp, Ctr Quantitat Sci, Clin Med Res Ctr Natl Hlth Res Inst, Natl Inst Canc Res Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Genom Med Natl Cheng Kung Univ, Coll Elect Engn & Comp Sci, Dept Comp Sci & Informat Engn Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Dept Biotechnol & Bioind Sci Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, PhD Program Translat Med
Keywords:	HER2 amplification Colorectal cancer Brain metastasis Heterogeneity Propensity score matching
Date:	2023
Issue Date:	2024-12-25 11:05:50 (UTC+8)
Publisher:	ELSEVIER SCI LTD
Abstract:	Background: The association between human epidermal growth factor receptor -2 (HER2) amplification and brain metastasis (BM) in patients having colorectal cancer (CRC) has been suggested but not yet established. This study investigated the expression pat-terns of HER2, its association with BM, and its prognostic value in patients having CRC.Methods: We retrospectively identified 99 patients having metastatic CRC (mCRC) and BM (the BM cohort) and compared them with a cohort of 249 patients having mCRC and without BM (the stage IV cohort) by propensity score matching. Immunohistochemical studies of HER2 on all available paraffin-embedded tumour samples, either from the primary tumour, the metastasis (brain and/or extracranial sites) or both, were performed and analysed. HER2 fluorescent in situ hybridisation was applied when necessary. The expression of HER2 was compared and correlated with survival.Results: HER2 amplifications were detected in 16 (18.4%) of 87 and 9 (3.6%) of 249 patients who had specimens available in the BM and stage IV cohorts, respectively (P < .001). After propensity score matching, HER2 amplification was significantly associated with BM (odds ratio: 5.38, P = .003). HER2 heterogeneity was frequently observed not only at the single tumour level but also in paired tumour samples. A marginally significant longer survival since BM was found in patients having HER2-amplified mCRC than in those without (P = .07).Conclusions: HER2 amplification was significantly associated with BM in patients having mCRC and might have prognostic value for survival since BM. Given the heterogeneity of HER2 expression, the testing of HER2 status on available tissues from both primary and met-astatic tumours should be encouraged.(c) 2022 Elsevier Ltd. All rights reserved.
Relation:	European Journal of Cancer, v.181
Appears in Collections:	[Offices] 456

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	5	View/Open

Loading...